Abstract
The microgravity of space travel is stressful to humans and produces physical changes including bone mineral loss, muscle atrophy, neuromuscular weakness, decline in work capacity, and fatigue (Fujii & Patten, 1992 ). An improved understanding of the mechanisms by which microgravity adversely affects both the physical and resultant/concomitant psychological and neurocognitive effects in humans, and more effective treatments to slow or halt these changes, will allow healthier, happier, and longer stays in space (Fujii & Patten) . However, limited opportunities to study orbital space flight have kept our understanding of the effects of microgravity in its infancy (Fujii & Patten) . Over the past, approximately 15 years, a ground-based model for simulating the effects of microgravity has been developed. Using this model, scientifically controlled experiments can be conducted to parse out the effects of simulated microgravity and evaluate preventative measures applied against those effects. It is hoped that countermeasures that oppose the effects of simulated microgravity will also be effective against the deleterious effects of the microgravity of space.
The effects of microgravity on humans are often studied by having participants confined to bedrest with a six-degree head-down tilt (antiorthostatic hypokinesia; Lathers, Charles, & Bungo, 1989) . Recently, we have proposed a model including hormonal modifications to accelerate the bone mineral loss and muscle atrophy seen in microgravity . It is important to understand both the neurocognitive and emotional effects of simulated microgravity, as well as implemented pharmacologic changes, in order to determine how such interventions may affect the well being of further research participants and future astronauts. To the extent that the catabolic effects of simulated microgravity are systemic, we might expect to observe neuropsychological effects similar to those observed in other cases of minimal brain dysfunction (MBD), such as those caused by malnutrition, exposure to toxic agents, or the residual effects of drug abuse. On the other hand, anabolic countermeasures would be expected to enhance some components of performance, as reflected by a lesser degree of MBD signs among participants who receive these countermeasures.
This study was conducted with the approval of the Louisiana State University Institutional Review Board in an effort to ascertain the neurocognitive and emotional effects of efforts to both enhance (Experiment 1) and retard or reverse (Experiment 2) the physically wasting effects of simulated microgravity. This two-experiment study represents a recombination of cells reported in previous physiological studies (Lovejoy, Smith, Bray, DeLany, & Rood, 1997a; Lovejoy et al., 1999) as a three-experiment study.
Experiment 1
All participants in both experiments gave informed consent to participate in this study that was a part of a larger study on the physiological effects of prolonged bedrest/simulated microgravity. After entering the Pennington Biomedical Research Center (PBRC) inpatient unit, participants were placed on a rigidly controlled and balanced diet excluding alcohol, caffeine, and cigarettes. Data were grouped into two experiments. Experiment 1 was conducted first, Experiment 2 followed thereafter. Methodological details of these studies have been published previously (Lovejoy et al., 1997a; Lovejoy, Smith, Bray, Veldhuis, & Rood, 1997b; Lovejoy et al., 1999) .
Method

Participants
Participants were admitted to the PBRC on an inpatient basis. The first week was utilized to acclimate them to the testing procedure and included three learning trials for each neuropsychological measure. Following this initial period, those in the Bedrest condition were placed with their head six degrees below their feet (antiorthostatic hypokinesia), and were not allowed to arise again for 28 days, while those in the Up condition were not restricted from normal daily activities except for limiting their participation in activities involving any strenuous exertion. Participants in the Bedrest condition remained at the PBRC for a total of 40 days, whereas participants in the Up condition stayed for 63 days. Testing continued during this period on a weekly basis, thus completing the five target test administrations. The first data point used in analysis was the last learning trial administered before any pharmacological interventions were introduced, and further data points were obtained from the four subsequent weekly test administrations. Pharmacological interventions were 3,5,3 -triiodothyronine (T3; n = 34) or a placebo (n = 6). T3 was given at a dose of 50-75 g per day (10-15 g per day five times a day). Following the 4 weeks of Bedrest or Up condition, testing in each condition was terminated. Those participants in the Bedrest condition were given several days on the unit for muscular reconditioning, as well as follow-up appointments to check for any occult health problems they may have incurred.
Groups
Experiment 1 consisted of 23 participants; six in the T3-Up condition, 11 in the T3-Bedrest condition, and six in the Placebo-Bedrest condition. Demographics for the participants in Experiment 1 can be seen in Table 1 .
Testing
Testing was always done in the morning following breakfast and typically during the weekend. Prior to testing, all participants were briefly interviewed to assure that they were not suffering from interfering physical symptoms such as headache or nausea. Testing included the Neurobehavioral Evaluation System 2 (NES2; Letz, 1993) , a computer administered test battery consisting of measures designed to test general neuropsychological performance on functions such as dexterity, concentration, and motor speed; the Symptom Check List 90 Revised (SCL-90-R; Derogatis, 1992) , and the Coping Responses Inventory (CRI; Moos, 1993) , both paper and pencil measures designed to assess endorsement of psychological symptoms. Each testing session took approximately 1.5 h to complete. Participants experiencing competing symptoms, such as headache, were not tested if they felt that their performance would be adversely affected or that testing would cause them undue discomfort. Instead, if they did not feel better within an hour, they were tested the next morning. This contingency was rare, but allowed flexibility to account for participants' needs without sacrificing any data acquisition.
The weekly neuropsychological and emotional test battery was designed to tap the intellectual domains of attention, concentration, reasoning, and cognitive flexibility; the motor domains of fine motor speed, coordination, pursuit skills, and gross motor strength; the memory domains of short term memory and learning, and long term recall for both verbal and non-verbal information; the visual-spatial domains of constructional ability and mental rotations; and the emotional domains of anxiety, depression, delirium, psychosis, anger, tension, fatigue, irritability, and somatic complaints.
Analysis
For Experiment 1, the factors of interest and respective analyses were as follows: (1) T3-Up versus Placebo-Bedrest, (2) T3-Up combined with Placebo-Bedrest versus T3-Bedrest, (3) T3-Up versus T3-Bedrest, and (4) Placebo-Bedrest versus T3-Bedrest.
Our rationale behind these comparisons was to investigate any neuropsychological and/or emotional differences between treatments imposed on participants in studies designed to simulate the atrophic wasting seen in microgravity. As such, we wanted to partial out the effects of both bedrest and T3 and see: (1) if T3 produced significantly different neuropsychological or emotional changes than bedrest alone, (2) if no difference was found between those taking T3 and those confined to bedrest, to see if those participants on T3-alone and those on bedrest-alone combined differed significantly in neuropsychological or emotional effect form those participants administered T3 and bedrest together, (3) if T3-alone and bedrest-alone differed, to see if those participants taking T3 differed neuropsychologically or emotionally from those taking T3 and confined to bedrest, and (4) if placebo participants confined to bedrest differed neuropsychologically or emotionally from those confined to bedrest and on T3.
The resultant data from the above groupings were subjected to repeated measures between groups analysis of variance testing for all 82 neurocognitive and psychological test measures. Analysis progressed in a step-wise fashion, Analysis 1 being conducted first. If Analysis 1 revealed a significant difference between the factors, Analyses 3 and 4 were then conducted to further define this difference. If Analysis 1 failed to reveal a significant difference, then Analysis 2 was conducted.
Finally, repeated measures analysis of variance testing was used to ascertain if there were any significant differences within a given group across time. As such, the scores for each of the 82 neurocognitive measures were compared for significant differences across the five administration times within each Experiment.
In an effort to ascertain the clinical importance of our findings, strength of association and effect size were computed for each significant between groups result. Strength of association was measured using eta squared (η 2 ), a coefficient which indicates the amount of total variation in the dependent variable that can be accounted for by the independent variable (Kiess, 1989) . Within this study, eta squared refers to the degree to which a significant result on a measure of cognitive or emotional functioning can be attributed to treatment classification. This coefficient is very similar to the coefficient of determination, or R 2 with which most are familiar (Kiess) . Effect size estimates (d) were then computed, measuring the differences among the paired treatment means beyond that expected from sampling error alone, and expressed in standardized units similar to Z-scores (Kiess) . In accordance with the discovery nature of this study, all analyses were conducted at alpha ≤ .05.
Results
Experiment 1 compared the neuropsychological and emotional effects associated with efforts to replicate the natural wasting that occurs in microgravity environments, by simulating it using head-down bedrest, and evaluated whether this wasting could be accelerated by the addition of T3. Of the 82 measures analyzed, significant results obtained are as follows: When comparing the Placebo-Bedrest condition with the T3-Up condition, the Placebo-Bedrest condition showed superior scores on finger tapping and hand-eye coordination, while endorsing more confusion and greater use of positive appraisal as a coping style. The T3-Up condition showed better scores on digit span backwards and associate recall, but produced more errors on switching attention. When comparing the T3-Up condition with the T3-Bedrest condition in secondary analysis, participants in the T3-Bedrest condition showed higher scores on finger tapping (both dominant and non-dominant hands) as well as more confusion and a higher positive symptom distress index. These findings all produced large effect sizes, a difference in means representing the value of one standard deviation or greater (Cohen, 1965) , ranging from d = 1.13 to 2.47 with a mean of d = 1.68. Strength of association ranged from η 2 = .242 to .604 with a mean η 2 of .405 (see Table 2 ). Repeated measures analysis of variance testing for differences across the five administration times produced 48 significant effects in Experiment 1. On the whole, 37.5% (18) of these effects were seen as being directly caused by one or more "outlier" performances and are not Table 3 .
Discussion
Experiment 1 revealed that participants in the Placebo-Bedrest condition performed better on some neuropsychological measures than the participants receiving T3 who were not confined to bedrest. This finding probably indicates a mild impairment in neurocognitive functioning resulting from T3 administration. However, participants in the Bedrest conditions (both those on T3 and placebo) also reported more confusion, a finding that most likely reflects on the disruption or disorientation resulting from prolonged maintenance of an alien posture.
Experiment 2
Experiment 2 was conducted to investigate the effects of countermeasures applied to thwart or reverse the muscle and bone atrophy induced in Experiment 1. Such countermeasures are of prime interest for space research and represent the forefront of such studies (Lathers et al., 1989; Lovejoy et al., 1997a Lovejoy et al., , 1997b Lovejoy et al., , 1999 .
Method
Participants
All participants in Experiment 2 were confined to bedrest and underwent a similar inpatient stay at the PBRC as those participants in Experiment 1 also confined to bedrest. Data acquisition also progressed along the 5-week time period as detailed in Experiment 1. In Experiment 2, all participants were given T3 at a dose of 50-75 g per day (10-15 g per day five times a day). Additionally, seven participants received testosterone (given as a loading dose of 75 g for three days and then 200 g per week for the three remaining weeks of the study), and six participants received alendronate (20 g per day; two doses of 10 g each with water). Finally, 11 participants received T3 alone with the countermeasure placebo. Following the 4 weeks of bedrest, as was done in Experiment 1, testing in each condition was terminated. Participants were then given several days on the unit for muscular reconditioning as well as follow-up appointments to check for any occult health problems they may have incurred.
Groups
Experiment 2 consisted of 24 participants; seven in the Testosterone (T) countermeasure plus T3-Bedrest condition, six in the Alendronate (AL) countermeasure plus T3-Bedrest condition, and 11 in the T3-Bedrest countermeasure placebo condition gleaned from Experiment 1. Demographics for Experiment 2 can be seen in Table 4 .
Testing
Testing for Experiment 2 proceeded exactly as in Experiment 1. The NES2, SCL-90-R, and CRI were again used, and the same efforts and precautions were taken to assure each participant's best effort while testing.
Analysis
For Experiment 2, the factors of interest and respective analyses were as follows (all participants were in Bedrest): (1) AL-T3 versus Testosterone-T3, (2) AL-T3 combined with Testosterone-T3 versus T3, (3) AL-T3 versus T3, and (4) Testosterone-T3 versus T3. Note. T3, 3,5,3 -triiodothyronine. All participants were in bedrest.
Our rationale behind these comparisons was to investigate any neuropsychological and/or emotional differences between different countermeasures imposed on participants confined to bed and in studies designed to retard the atrophic wasting seen in microgravity. As such, we wanted to partial out the effects of both testosterone and alendronate in the context of T3 and therefore see: (1) if AL administered with T3 produced significantly different neuropsychological or emotional changes than Testosterone administered with T3, (2) if no difference was found between those taking T3 and AL and those taking T3 and testosterone, to see if those participants on T3 and AL and those on T3 and testosterone combined differed significantly in neuropsychological or emotional effect form those participants administered T3 and placebo, (3) if those on T3 and AL and those on T3 and testosterone differed, to see if those participants taking T3 and AL differed neuropsychologically or emotionally from those taking T3 and placebo, and (4) to see if those participants taking T3 and testosterone differed neuropsychologically or emotionally from those taking T3 and placebo.
The resultant data from the above groupings was subjected to repeated measures, between groups analysis of variance testing for all 82 neurocognitive and psychological test measures as was done in Experiment 1. Analysis progressed in a step-wise fashion, Analysis 1 being conducted first. If Analysis 1 revealed a significant difference between the factors, Analyses 3 and 4 were then conducted to further define this difference. If Analysis 1 failed to reveal a significant difference, then Analysis 2 was conducted.
Strength of association (η 2 ) and effect size (d) were determined for Experiment 2. Finally, in accordance with the discovery nature of this study, all analyses were conducted at alpha ≤ .05.
Results
Experiment 2 compared the neurocognitive and emotional effects associated with administering one of two different countermeasures (alendronate or testosterone) to prevent the wasting that was accelerated in the T3 plus Bedrest condition. Experiment 2 showed two patterns of results. First, the AL-T3 condition scored better than the Testosterone-T3 (T-T3) condition on a task of hand-eye coordination, but worse on two measures of response time (color word response time and simple reaction time). The second pattern involved the report of psychological symptoms on self-report measures. Findings indicated that both countermeasures (testosterone and alendronate) were effective at promoting improved psychological adjustment over the T3 and placebo conditions during the Bedrest condition. The AL-T3 condition scored somewhat higher than T-T3 on a measures of memory symptoms, two measures of confusion, and measures of depression, fatigue, somatization, obsessive compulsive traits, and positive symptom total. Of these measures, visual inspection revealed that the T3 and placebo conditions had the greatest self-report of negative psychological symptoms, showing more endorsement than either the AL-T3 or T-T3 conditions on most of the above measures of psychological symptoms. These findings also produced large effect sizes (Cohen, 1965) ranging from d = 1.11 to 2.03 with a mean of d = 1.55. Strength of association ranged from η 2 = .235 to .507 with a mean η 2 of .372 (see Table 5 ).
Repeated measures analysis of variance testing for differences across the five administration times in Experiment 2 produced 55 significant effects. On the whole, 50.9% (18) of these effects were seen as being directly caused by one or more "outlier" performances and are not readily interpretable as showing either an upward or downward trend, 34.5% (19) showed general improvement in functioning or self-report, and 14.6% (8) represented worsening in functioning or self-report. Rates of neurocognitive practice effects and self-reported psychological change are presented in Table 6 . 
Discussion
Experiment 2 comparisons revealed an advantage in coordination for the Testosterone-T3 treated group over the Alendronate-T3 group, but just the opposite for reaction time, indicating a superiority in motor accuracy but with a decrement in speed. Also, T3 and testosterone, and to a lesser degree, T3 and alendronate, were associated with less self-reported emotional distress than T3 and placebo, suggesting that the countermeasures mitigated some of the psychological discomfort found among participants in the T3 and placebo treatment during Bedrest.
General discussion
The various magnitudes of all significant differences seen in this study represent rather large effects (Cohen, 1965) , but were observed on relatively few measures. Both Experiments 1 and 2 looked at each of the 82 measures, contrasting group performances with up to three analyses on each, thus yielding a potential total of 492 analyses (the actual number was 270). As an alternative to Bonferroni correction, and in order to assure that the present findings did not capitalize on chance, we investigated the total number of significant group differences. Setting alpha at ≤.05, 5% of the 270 analyses or 13.5 of them, would be expected to reach significance by chance alone. Analysis found 35 significant group differences in Experiments 1 and 2 combined. Also, a number of the variables were found to be significant in both Experiments 1 and 2, suggesting that these may represent genuine effects (e.g., hand-eye coordination, confusion, Positive Symptoms Distress Index).
For the variables that reached the P ≤ .05 level of significance, mean differences between paired treatment group means averaged 1.62 standard deviations for the entire experiment and never dropped below one standard deviation; on several instances they even approached or exceeded two standard deviations. The size of these differences warrants attention by persons engaged in studies of simulated microgravity/antiorthostatic hypokinesia, and/or studies where substances such as alendronate, testosterone, or T3 are applied. Although the observed neurocognitive effects likely pose no immediate danger for research participants, the significantly greater self-report of psychological symptoms by some treatment groups (T3-alone and Bedrest-only conditions) may be of clinical importance as they reflect on the somewhat aversive nature of the prolonged head-down bedrest procedure.
Experiment 2 of this study was conducted in an effort to mitigate the wasting typically seen in microgravity/antiorthostatic hypokinesia environments and enhanced with countermeasures such as T3. The use of alendronate and testosterone requires further research to partial out the degree of both the positive effects, such as lower self-report of emotional distress and improved coordination, and the negative effects, such as increased reaction time, which these drugs may induce in future astronauts and those receiving them as medication. Overall, however, the addition of countermeasures to the Bedrest and T3 protocol appears to partially mitigate some of the accumulated aversiveness that results from the prolonged bedrest experience, along with beneficially impacting the physical atrophic changes of antiorthostatic hypokinesia .
